ARVN Stock Risk & Deep Value Analysis
Arvinas Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on ARVN
We analyzed Arvinas Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARVN through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
ARVN Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Arvinas Inc (ARVN)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$883.21M
ARVN Deep Value Analysis
Compare ARVN to Similar Stocks
See how Arvinas Inc stacks up against related companies in our head-to-head analysis.
ARVN Red Flags & Warning Signs
- âš
Negative or inconclusive data from ongoing clinical trials (especially ARV-471)
- âš
Safety concerns or adverse events reported in clinical studies
- âš
Regulatory hurdles or delays in drug approval processes
- âš
Increased cash burn rate leading to further dilution without significant clinical progress
Unlock ARVN Red Flags & Risk Warnings
Create a free account to see the full analysis
ARVN Financial Health Metrics
Market Cap
$883.21M
ARVN Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is derived from its pioneering work in PROTAC technology and a robust intellectual property portfolio. Its durability is expanding as the company advances its pipeline, validates the platform, and secures strategic partnerships, making it increasingly difficult for new entrants to replicate its scientific lead and clinical progress. However, it is vulnerable to superior scientific advancements or aggressive patent challenges.
ARVN Competitive Moat Analysis
Sign up to see competitive advantages
ARVN Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated Late February/Early March 2026)
- •Updates from ongoing clinical trials (Phase 1/2 programs, particularly ARV-102 & ARV-766)
- •Presentations at major medical conferences (e.g., ASCO, SABCS) with pipeline progress updates
Medium-Term (6-18 months)
- •Potential for interim analysis updates or guidance on topline data timing for ARV-471 (Velexbru) Phase 3 trial
- •Initiation of new clinical trials for existing or novel PROTAC candidates
- •Expansion of Pfizer collaboration or new strategic partnerships based on platform validation
Long-Term (18+ months)
- •Topline data readout for ARV-471 (Velexbru) Phase 3 trial in ER+/HER2- breast cancer
- •Regulatory submission and potential approval for Velexbru in target indications
- •Commercial launch and market penetration of Velexbru by Pfizer
- •Expansion of PROTAC platform into non-oncology indications and broader therapeutic areas
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
ARVN Bull Case: What Could Go Right
- ✓
Positive clinical trial data readouts, especially for ARV-471
- ✓
Updates on cash runway and successful financing rounds (if necessary)
- ✓
Progression of other pipeline assets into later-stage clinical development
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
